LDHA and breast cancer: Because only strongly ALDH-positive cells show a more aggressive phenotype typical of E-CSCs [103], it might relevant to evaluate whether the stem cell biomarker ALDH could be associated with trastuzumab efficacy in a cut-off-dependent manner in cHER2+ versus cHER2− BC.